Dorsavi Ltd. · ASX:DVL
Dorsavi — Shareholder Meeting (November 2017)
18 slides from Dorsavi's shareholder meeting presentation, Nov 23, 2017
Slide 1: Cover letter to ASX: 2017 AGM Opening Addresses and CEO Presentation
For personal use only 23 November 2017 Market Announcements Office Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam 2017 Annual General Meeting Opening Addresses and CEO Presentation We attach a copy of the opening addresses to be provided by retiring Chairman a
Slide 2: Opening Addresses by Herb Elliott and Greg Tweedly
DORSAVI LTD For personal use only AGM 23 NOVEMBER 2017 OPENING ADDRESSES BY HERB ELLIOTT AND GREG TWEEDLY ADDRESS BY HERB ELLIOTT Good morning ladies and gentlemen, My name is Herb Elliott and as Chairman of dorsaVi, and I am pleased to welcome you to our fourth Annual General Meeting as an ASX list
Slide 3: Address by Greg Tweedly (continued)
roles. Caroline brings exceptional experience to entrepreneurial and transitional businesses applying a strong business acumen to resolve complex situations and help find a clear path forward to drive positive business outcomes. Caroline will Chair the Audit and Risk Committee. We welcome her to the
Slide 4: About dorsaVi and contacts
For more information or to arrange an interview, contact: MEDIA INVESTOR Megan Connell Rebecca Wilson dorsaVi Buchan Consulting 0416 116 526 0417 382 391 For personal use only mconnell@dorsavi.com rwilson@buchanwe.com.au About dorsaVi dorsaVi (ASX: DVL) is an ASX company focused on developing innova
Slide 5: Inspiring the World to Move Well
For personal use only // 1 INSPIRING THE WORLD TO MOVE WELL dorsaVi AGM 23 NOVEMBER 2017 Commercial in Confidence
Slide 6: FY Milestones
// 2 FY 17 Milestones For personal use only Aug 2016 Sep 2016 Oct 2016 Oct 2016 Dec 2016 Release of dorsaVi awarded Launch of US-based dorsaVi and Mizuno Launch of myViSafe™ ViPerform Future Industries patient registry work together in and US sales agent for AMI in US Manufacturing pilot retail prog
Slide 7: Investment Highlights
// 3 INVESTMENT HIGHLIGHTS • First mover advantage, leader with medical grade wearable technology – FDA, CE Mark, TGA approved • Three attractive markets – Occupational Health & Safety, Clinical, and Elite Sports For personal use only • Across three geographic markets – US, UK and Australia • FY17 r
Slide 8: Strong Foundation for Growth
// 4 STRONG FOUNDATION FOR GROWTH • Patent protected movement algorithms For personal use only on medical-grade sensor technology • Function-specific applications which • OHS solution to determine, measure and mitigate high risk activities deliver meaningful movement data to our • Significant appeti
Slide 9: Product Evolution: Keeping First Mover Advantage
// 5 PRODUCT EVOLUTION: KEEPING FIRST MOVER ADVANTAGE For personal use only Benefits of mini sensors • 10 second start up (vs 3 mins) • Significant reduction in COGS • Training 10 min call (vs 4 hrs F2F) • Smaller and lighter • Higher data rates • Mobile use case (remote) • Sell on line • Scalable f
Slide 10: Execution Across the Product Lines
// 6 EXECUTION ACROSS THE PRODUCT LINES ViSafe (OHS) For personal use only • ViSafe growing well with major brands in all three geographic markets ($40k-$300k contracts) • myViSafe - self managed solution within ViSafe portfolio creating annuity revenue ($10k p.a.) • Scalable across small to large c
Slide 11: Movement Continuum - Blending Clinical & Workplace
// 7 MOVEMENT CONTINUUM - BLENDING CLINICAL & WORKPLACE PREVENTION RECOVERY For personal use only Dynamic movement profile Identify & prioritise movement risk Tailor RTW to individual Validate RTW / Suitable Duties Benchmark for individual worker Validate control strategies Track progress Reduce ris
Slide 12: Clinical Scale in the US Market
// 8 CLINICAL SCALE IN THE US MARKET dorsaVi clinical sites and number of PT’s by state For personal use only 284,000 Physical Therapists in the USA • Franchise model with acquisitions occurring • Commercially minded • Less hands on • Treat multiple patients at a time (1:4) • More tech savvy • Outre
Slide 13: Financial Overview
// 9 FINANCIAL OVERVIEW For personal use only 2014 2015 2016 2017 Q1 2018 Revenue 529,380 1,358,218 3,019,928 3,466,027 958,000* EBITDA (4,079,768) (8,597,121) (5,799,632) (4,542,770) N/A Loss from continuing (3,562,024) (8,036,161) (5,237,102) (3,876,248) N/A operations Cash position $13.94M $5.74M
Slide 14: Operational Changes
// 10 OPERATIONAL CHANGES For personal use only • Focus has been on product optimization, building a solid foundation of large customers and creating the right structure for growth • By structure we mean: 1. Firstly, getting the right revenue model that allows us to build annuity revenue 2. Secondly
Slide 15: Operational Changes
// 11 OPERATIONAL CHANGES • For personal use only Firstly, to promote Matt May to the role of General Manager Operations internationally. • CEO to focus on strategic relationships in the US and Europe and relocate to the US. Mark Heaysman will continue his role as Head of Sales & Operations US. • Ma
Slide 16: Board and Senior Management
For personal use only BOARD AND SENIOR MANAGEMENT (from 24/11/2017) // 12 Chairman Non Executive Director Non Executive Director Non Executive Director Greg Tweedly Michael Panaccio Ash Attia Caroline Elliott Director & CEO Andrew Ronchi General Manager Matt May CFO CIO CPO CMO Head of Sales and Hea
Slide 17: Strategic Relationships Will Enhance Growth
// 13 STRATEGIC RELATIONSHIPS WILL ENHANCE GROWTH For personal use only MEDICAL DEVICES PHARMACEUTICALS MAJOR CLINICAL GROUPS UNIVERSITIES • Large companies with a • Independent evidence on • Aiming to reduce • Develop better treatment special interest in how their drugs are admissions protocols mov
Slide 18: Forward Looking
// 14 FORWARD LOOKING For personal use only • Growing annuity revenue from the strong US clinical market • Continue to win repeat contracts with ViSafe projects • New annuity revenue stream from myViSafe in OHS market • Higher volumes will reduce COGS • Secure deals with strategic partners searching